Allogeneic hematopoietic stem cell transpalntation using Thymoglobulin for patients with T-cell malignancy
Not Applicable
- Conditions
- T-cell malignancy
- Registration Number
- JPRN-UMIN000015736
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
(1) severe organ failure (2) uncontrolled hypertension (3) HIV infection (4) uncontrolled active infection (5) uncontrolled CNS invasion (6) pregnancy (7) psychological disorder (8) allergy to drugs used in this study (9) if the physician consider as inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Probability of survival with engraftment at 60 days after allogeneic HSCT
- Secondary Outcome Measures
Name Time Method